383 related articles for article (PubMed ID: 15936733)
1. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease.
Saravanan KS; Sindhu KM; Mohanakumar KP
Brain Res; 2005 Jul; 1049(2):147-55. PubMed ID: 15936733
[TBL] [Abstract][Full Text] [Related]
2. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
[TBL] [Abstract][Full Text] [Related]
3. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion.
Sindhu KM; Saravanan KS; Mohanakumar KP
Brain Res; 2005 Jul; 1051(1-2):25-34. PubMed ID: 15992782
[TBL] [Abstract][Full Text] [Related]
4. Rotenone increases glutamate-induced dopamine release but does not affect hydroxyl-free radical formation in rat striatum.
Leng A; Feldon J; Ferger B
Synapse; 2003 Dec; 50(3):240-50. PubMed ID: 14515342
[TBL] [Abstract][Full Text] [Related]
5. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine.
Sindhu KM; Banerjee R; Senthilkumar KS; Saravanan KS; Raju BC; Rao JM; Mohanakumar KP
Pharmacol Biochem Behav; 2006 Jun; 84(2):321-9. PubMed ID: 16820197
[TBL] [Abstract][Full Text] [Related]
6. Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle.
Norazit A; Meedeniya AC; Nguyen MN; Mackay-Sim A
Brain Res; 2010 Nov; 1360():119-29. PubMed ID: 20807515
[TBL] [Abstract][Full Text] [Related]
7. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.
Testa CM; Sherer TB; Greenamyre JT
Brain Res Mol Brain Res; 2005 Mar; 134(1):109-18. PubMed ID: 15790535
[TBL] [Abstract][Full Text] [Related]
8. Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers.
Sengstock GJ; Olanow CW; Menzies RA; Dunn AJ; Arendash GW
J Neurosci Res; 1993 May; 35(1):67-82. PubMed ID: 7685399
[TBL] [Abstract][Full Text] [Related]
9. Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra.
Sengstock GJ; Olanow CW; Dunn AJ; Barone S; Arendash GW
Exp Neurol; 1994 Nov; 130(1):82-94. PubMed ID: 7529713
[TBL] [Abstract][Full Text] [Related]
10. Acute intranigral homocysteine administration produces stereotypic behavioral changes and striatal dopamine depletion in Sprague-Dawley rats.
Chandra G; Gangopadhyay PK; Senthil Kumar KS; Mohanakumar KP
Brain Res; 2006 Feb; 1075(1):81-92. PubMed ID: 16487496
[TBL] [Abstract][Full Text] [Related]
11. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease.
Caboni P; Sherer TB; Zhang N; Taylor G; Na HM; Greenamyre JT; Casida JE
Chem Res Toxicol; 2004 Nov; 17(11):1540-8. PubMed ID: 15540952
[TBL] [Abstract][Full Text] [Related]
12. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
13. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone.
Fleming SM; Zhu C; Fernagut PO; Mehta A; DiCarlo CD; Seaman RL; Chesselet MF
Exp Neurol; 2004 Jun; 187(2):418-29. PubMed ID: 15144868
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
[TBL] [Abstract][Full Text] [Related]
15. Sodium salicylate protects against rotenone-induced parkinsonism in rats.
Madathil SK; Karuppagounder SS; Mohanakumar KP
Synapse; 2013 Aug; 67(8):502-14. PubMed ID: 23447126
[TBL] [Abstract][Full Text] [Related]
16. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
Verma R; Nehru B
Neurochem Int; 2009 Nov; 55(6):369-75. PubMed ID: 19375462
[TBL] [Abstract][Full Text] [Related]
17. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model.
Blandini F; Levandis G; Bazzini E; Nappi G; Armentero MT
Eur J Neurosci; 2007 Jan; 25(2):397-405. PubMed ID: 17284180
[TBL] [Abstract][Full Text] [Related]
18. Alpha-synuclein and tyrosine hydroxylase expression in acute rotenone toxicity.
Luo C; Rajput AH; Akhtar S; Rajput A
Int J Mol Med; 2007 Mar; 19(3):517-21. PubMed ID: 17273802
[TBL] [Abstract][Full Text] [Related]
19. Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model.
Saravanan KS; Sindhu KM; Mohanakumar KP
J Pineal Res; 2007 Apr; 42(3):247-53. PubMed ID: 17349022
[TBL] [Abstract][Full Text] [Related]
20. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
Alam M; Schmidt WJ
Behav Brain Res; 2004 Aug; 153(2):439-46. PubMed ID: 15265640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
